A low-dose combination of CaHMB, CBP, and HA delays age-related muscle and bone loss during the transition to old age, with comprehensive benefits potentially mediated by the muscle–bone axis.
Chen et al. (2026) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: